Register entry
MELINTA SUBSIDIARY CORP
- Registered sites
- 0
- Drug products
- 0
- Live patents
- 16
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
16Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| BAXDELA | DELAFLOXACIN MEGLUMINE | Oct 2026 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Mar 2029 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Sept 2029 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Dec 2029 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Jun 2031 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | May 2032 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Feb 2033 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Mar 2034 |
| BAXDELA | DELAFLOXACIN MEGLUMINE | Jun 2034 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.